Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

PSA screening: the USPSTF got it right.

Lefevre M.

J Fam Pract. 2013 Nov;62(11):617, 619. No abstract available.

PMID:
24288702
2.

PSA screening: the USPSTF got it wrong.

Scherger JE.

J Fam Pract. 2013 Nov;62(11):616, 618. No abstract available.

3.

Death knell for PSA screening?

Mani H.

Natl Med J India. 2011 Nov-Dec;24(6):380. No abstract available.

PMID:
22680272
4.

Risks of PSA screening now better understood.

Peres J.

J Natl Cancer Inst. 2013 Nov 6;105(21):1590-2. doi: 10.1093/jnci/djt328. Epub 2013 Oct 18. No abstract available.

PMID:
24142893
5.

USPSTF finds little evidence to support advising PSA screening in any man.

Slomski A.

JAMA. 2011 Dec 21;306(23):2549-51. doi: 10.1001/jama.2011.1804. No abstract available.

PMID:
22187266
6.

Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Moul JW.

BJU Int. 2011 Jul;108(1):44-8. doi: 10.1111/j.1464-410X.2010.09812.x. Epub 2010 Nov 2.

7.

Prostate-specific antigen screening for prostate cancer in older men in the United States of America.

Black A, Berg CD.

Gerontology. 2012;58(4):331-6. doi: 10.1159/000334242. Epub 2012 Feb 16.

PMID:
22343605
8.

Missing the mark on prostate-specific antigen screening.

Miller DC, Hollenbeck BK.

JAMA. 2011 Dec 28;306(24):2719-20. doi: 10.1001/jama.2011.1879. No abstract available.

PMID:
22203542
9.

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

Barry MJ, Mulley AJ Jr.

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10. No abstract available.

PMID:
19276451
10.

Screening for prostate cancer: prostate-specific antigen testing is not effective.

Hitzeman N, Molina M.

Am Fam Physician. 2011 Apr 1;83(7):802-4. No abstract available.

11.

The science and art of prostate cancer screening.

Yao SL, Lu-Yao GL.

J Natl Cancer Inst. 2011 Mar 16;103(6):450-1. doi: 10.1093/jnci/djr047. Epub 2011 Feb 24. No abstract available.

PMID:
21350220
12.

American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.

Carter HB.

BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. Review.

13.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

14.

States renewing attention to prostate cancer.

Rossiter C.

NCSL Legisbrief. 2012 Sep;20(36):1-2. No abstract available.

PMID:
23072022
15.

Helping men make decisions about PSA tests.

[No authors listed]

BMJ. 2013 Jul 31;347:f4785. doi: 10.1136/bmj.f4785. No abstract available.

PMID:
23903252
16.

Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Belpomme D, Irigaray P.

J Natl Cancer Inst. 2010 Apr 7;102(7):506-7. doi: 10.1093/jnci/djq045. Epub 2010 Feb 26. No abstract available.

PMID:
20190186
17.

Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.

Djavan B.

Eur Urol. 2010 Jun;57(6):928-9. doi: 10.1016/j.eururo.2010.03.002. Epub 2010 Mar 9. No abstract available.

PMID:
20304552
18.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.

PMID:
22801674
19.

New PSA guidelines discourage overscreening.

Peres J.

J Natl Cancer Inst. 2012 Jan 4;104(1):8-9. doi: 10.1093/jnci/djr539. Epub 2011 Dec 14. No abstract available.

PMID:
22173585
20.

Should we screen for prostate cancer? A re-examination of the evidence.

Del Mar CB, Glasziou PP, Hirst GH, Wright RG, Hoffmann TC.

Med J Aust. 2013 Jun 3;198(10):525-7. No abstract available.

PMID:
23725255

Supplemental Content

Support Center